🇺🇸 FDA
Pipeline program

Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects

P24-03

Phase 1 other active

Quick answer

Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects for Narcolepsy, Narcolepsy with cataplexy is a Phase 1 program (other) at Bioprojet Pharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Bioprojet Pharma
Indication
Narcolepsy, Narcolepsy with cataplexy
Phase
Phase 1
Modality
other
Status
active

Clinical trials